Evidence map›Paper›PMID 25533534›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus.

Nobuhiro Kawai, Noriaki Sakai, Masashi Okuro, Sachie Karakawa, Yosuke Tsuneyoshi, Noriko Kawasaki, Tomoko Takeda, Makoto Bannai, Seiji Nishino

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07633080 (Efficacy and Safety of Add-on Magnesium Bisglycinate in Major Depressive Disorder), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07633080 narecruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Add-on Magnesium Bisglycinate in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

TypeinterventionalSponsorAll India Institute of Medical Sciences, BhubaneswarRan2026 to 2028Enrolled84ConditionsMajor Depressive DisorderArmsMagnesium Bisglycinate, Microcrystalline cellulose
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Combined Effects ofFoods (Basel, Switzerland) · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Nobuhiro KawaiInstitute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
Noriaki SakaiSleep and Circadian Neurobiology laboratory, Stanford University School of Medicine, Stanford, CA, USA.
Masashi Okuro1] Sleep and Circadian Neurobiology laboratory, Stanford University School of Medicine, Stanford, CA, USA [2] Department of Geriatric Medicine, Kanazawa Medical University, Kanazawa, Japan.
Sachie KarakawaInstitute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
Yosuke TsuneyoshiInstitute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
Noriko KawasakiInstitute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
Tomoko TakedaInstitute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
Makoto BannaiInstitute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
Seiji NishinoSleep and Circadian Neurobiology laboratory, Stanford University School of Medicine, Stanford, CA, USA.
Ajinomoto (Japan) · JPStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of glycine as a therapeutic option for improving sleep quality is a novel and safe approach. However, despite clinical evidence of its efficacy, the details of its mechanism remain poorly understood. In this study, we investigated the site of action and sleep-promoting mechanisms of glycine in rats. In acute sleep disturbance, oral administration of glycine-induced non-rapid eye movement (REM) sleep and shortened NREM sleep latency with a simultaneous decrease in core temperature. Oral and intracerebroventricular injection of glycine elevated cutaneous blood flow (CBF) at the plantar surface in a dose-dependent manner, resulting in heat loss. Pretreatment with N-methyl-D-aspartate (NMDA) receptor antagonists AP5 and CGP78608 but not the glycine receptor antagonist strychnine inhibited the CBF increase caused by glycine injection into the brain. Induction of c-Fos expression was observed in the hypothalamic nuclei, including the medial preoptic area (MPO) and the suprachiasmatic nucleus (SCN) shell after glycine administration. Bilateral microinjection of glycine into the SCN elevated CBF in a dose-dependent manner, whereas no effect was observed when glycine was injected into the MPO and dorsal subparaventricular zone. In addition, microinjection of D-serine into the SCN also increased CBF, whereas these effects were blocked in the presence of L-701324. SCN ablation completely abolished the sleep-promoting and hypothermic effects of glycine. These data suggest that exogenous glycine promotes sleep via peripheral vasodilatation through the activation of NMDA receptors in the SCN shell.

Indexed as

AnimalsAutonomic AgentsBody TemperatureDose-Response Relationship, DrugGlycineHypnotics and SedativesMalePreoptic AreaProto-Oncogene Proteins c-fosRandom AllocationRats, Sprague-DawleyRats, WistarReceptors, GlycineReceptors, N-Methyl-D-AspartateRegional Blood FlowSkinAutonomic AgentsGlycineHypnotics and SedativesProto-Oncogene Proteins c-fosReceptors, GlycineReceptors, N-Methyl-D-Aspartate

Identifiers

PMID25533534
PMCPMC4397399
OpenAlexW2065545869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.